Table 1 Characteristics of the study population.

From: Expansion of different subpopulations of CD26−/low T cells in allergic and non-allergic asthmatics

  AA NAA R HC
N 100 92 44 32
Age (mean (range)) 36 (18–68) 52 (22–72) 35 (18–55) 43 (22–61)
Sex (M/F) 46/54 22/70 25/19 15/17
Disease control
Yes 83 75 44
No 17 17 0
Baseline treatment
ICS-LABA 79 75 0 0
ICS 16 4 0 0
OCS 1 0 0 0
Antileukotrienes 41 31 11 0
Anticholinergic 15 28 0 0
Roflumilast 0 2 0 0
Prednisone 0 5 0 0
Biochemical, hematological and pulmonary function parameter
FEV1 (%) 97.0 (88.3–107.0)# 97.0 (73.2–112.0)# 108.0 (99.0–119.0)
FEV1/FVC (%) 76.0 (70.5–80.4)# 73.7 (66.2–80.0)# 83.4 (79.0–87.2)
Neutrophils (103 cells/μL) 3.70 (3.03–4.29) 3.56 (3.08–4.30) 3.56 (2.89–3.99) 3.02 (2.28–4.05)
Lymphocytes (103 cells/μL) 1.99 (1.67–2.29) 1.94 (1.58–2.34) 2.14 (1.78–2.58) 1.99 (1.53–2.49)
Monocytes (103 cells/μL) 0.40 (0.31–0.47) 0.37 (0.30–0.51) 0.39 (0.31–0.46) 0.39 (0.33–0.49)
Eosinophils (103 cells/μL) 0.29 (0.20–0.47)&# 0.28 (0.16–0.41)& 0.22 (0.14–0.29) 0.13 (0.09–0.22)
Basophils (103 cells/μL) 0.04 (0.03–0.05) 0.03 (0.02–0.05) 0.04 (0.02–0.05) 0.03 (0.02–0.05)
ESR (1 h; mm) 7.5 (4.0–15.0)* 12.0 (7.0–20.8)#& 8.0 (2.0–14.7) 7.5 (2.0–10.0)
TGF-β1 (ng/mL) 14751 (11882–17299) 13712 (10118–18149) 13957 (8691–19056) 15654 (11552–18620)
sCD25 (ng/mL) 2.86 (2.29–3.64) 3.02 (2.42–3.90) 2.77 (2.29–4.09) 2.77 (2.3–4.13)
IgE (IU/mL) 167.5 (72.0–301.0)*#& 28.0 (10.0–60.5)# 66.0 (24.0–115.0) 15.0 (5.7–55.7)
IgG (mg/dL) 1075 (943–1200) 1035 (898–1160) 1010 (913–1200)
IgG1 (mg/dL) 659 (563–745)* 573 (461–677) 617 (530–743)
IgG2 (mg/dL) 346 (337–429) 337 (263–429) 315 (259–411)
IgG3 (mg/dL) 33 (23–49) 37 (28–56) 34 (28–48)
IgG4 (mg/dL) 48 (27–85)# 40 (19–67) 34 (21–51)
IgA (mg/dL) 226 (167–295) 213 (159–263) 191 (133–274)
IgM (mg/dL) 98.5 (72–147) 113 (75–151) 111 (69–166)
TNF (pg/mL) 6.8 (5.5–8.5) 6.2 (5.4–7.6) 6.8 (5.2–9.1)
  1. AA, allergic asthmatics; HC, healthy controls; NAA, non-allergic asthmatics; R, rhinitis patients.
  2. Data are presented as median value (IQR1–3), unless otherwise expressed.
  3. Kruskal–Wallis test followed by Dunn’s multiple comparison test (P < 0.05). *AA vs NAA; #asthma vs R; &asthma vs HC.